$AIMT If you are holding long term, you don't even worry about the up and down in the past week. The global market size for peanut allergy is 3.4B. The company sits at 1.9B market cap. The only solution before palforzia was epipen, and it might not work well everytime. We are talking of at least a billion dollar revenue for a 1.9B company. In biotech, PE ratio is usually ranging from 25 to 40. It means $AMIT is likely to grow to 25B to 40B valuation in a conservative estimation in a few years. In the mean time, they are gonna have more products in the pipeline for other allergies. So just sit tight with πŸ’Žβœ‹.
  • 7
  • 8